1. Neurological Disease

Neurological Disease

Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W016443
    L-m-Tyrosine 587-33-7 ≥98.0%
    L-m-Tyrosine is an unnatural amino acid. L-m-Tyrosine reduces dopamine, norepinephrine and serotonin in rats. L-m-Tyrosine has potential in the research of Parkinsons disease, Alzheimers disease, and arthritis.
    L-m-Tyrosine
  • HY-W181102
    NFAT Inhibitor-2 422546-87-0 98.02%
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).
    NFAT Inhibitor-2
  • HY-N0210S16
    D-Galactose-13C6 74134-89-7 ≥99.0%
    D-Galactose-13C6 is the C13 labeled D-Galactose (HY-N0210). D-Galactose is a natural aldohexose and C-4 epimer of glucose[1][2].
    D-Galactose-13C6
  • HY-W015309S1
    Decanoic acid-d19 88170-22-3 98.4%
    Decanoic acid-d199 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].
    Decanoic acid-d19
  • HY-14197
    Clorgyline 17780-72-2 99.76%
    Clorgyline (M&B 9302) is an orally active, blood-brain barrier permeable and selective monoamine oxidase A (MAO-A) inhibitor. Clorgyline's selective inhibition of MAO-A leads to reduced metabolism of neurotransmitters such as serotonin (5-hydroxytryptamine), which accumulates in the brain. Clorgyline can be used in the study of depression and neurodegenerative diseases.
    Clorgyline
  • HY-B0194
    Tizanidine 51322-75-9 99.58%
    Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.
    Tizanidine
  • HY-B1746
    Pyridoxamine 5′-phosphate 529-96-4 99.22%
    Pyridoxamine 5′-phosphate is the active form of vitamin B6 bound to phosphoric acid. Pyridoxamine 5′-phosphate is the aminated form of pyridoxal 5'-phosphate hydrate (HY-W011727A) and as co-factor of a variety of enzymes central metabolite, potent antioxidant, vitamin B6 vitamer and enzyme substrate. Pyridoxamine 5′-phosphate can be interconverted with pyridoxal 5'-phosphate hydrate.
    Pyridoxamine 5′-phosphate
  • HY-B1833
    Afloqualone 56287-74-2 99.94%
    Afloqualone (HQ-495) is an orally active central muscle relaxant and antivertiginous agent that can increase the sensitivity of GABA receptors in neurons of the lateral vestibular nucleus. Afloqualone (HQ-495) can be used in the research of low back pain and neck-arm-shoulder syndrome.
    Afloqualone
  • HY-NP139
    Mouse Laminin
    Mouse Laminin is a Laminin from mouse that can be used as a thin coating on tissue culture surfaces or as a soluble additive to culture media.
    Mouse Laminin
  • HY-100907
    (±)-Acetylcarnitine chloride 2504-11-2 ≥99.0%
    (±)-Acetylcarnitine chloride (Acetyl dl-carnitine chloride) is a weak cholinergic agonist with cholinergic properties. (±)-Acetylcarnitine chloride is an important intermediate in lipid metabolism.
    (±)-Acetylcarnitine chloride
  • HY-160505
    RO-275 2648837-04-9 ≥99.0%
    RO-275 (compound 29) is a potent, selective and orally active HCN1 inhibitor with IC50 values of 0.046, 14.3, 4.6, 13.9 µM for HCN1, HCN2, HCN3, HCN4, respectively. RO-275 rescues decremented working memory. RO-275 has the potential for the research of cognitive dysfunction in brain disorder.
    RO-275
  • HY-W102714
    1,2-Cyclohexylenedinitrilotetraacetic acid 482-54-2 ≥98.0%
    1,2-Cyclohexylenedinitrilotetraacetic acid (CDTA) is a chelating agent. 1,2-Cyclohexylenedinitrilotetraacetic acid has an ability to remove manganese from brain and liver (in vivo) and their sub-cellular fractions (in vitro), of rats pretreated with manganese sulphate.
    1,2-Cyclohexylenedinitrilotetraacetic acid
  • HY-W001158S
    N,N-Dimethylglycine-d6 hydrochloride 347840-03-3 ≥99.0%
    N,N-Dimethylglycine-d6 (Dimethylglycine-d6) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects.
    N,N-Dimethylglycine-d6 hydrochloride
  • HY-103242
    CRANAD-2 1193447-34-5 ≥98.0%
    CRANAD-2 is a near-infrared (NIR) Aβ plaque-specific fluorescent probe. CRANAD 2 penetrates the blood brain barrier and has a high affinity for Aβ aggregates with a Kd of 38 nM.
    CRANAD-2
  • HY-13993
    Ro 25-6981 169274-78-6 99.55%
    Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD).
    Ro 25-6981
  • HY-100457
    IC87201 866927-10-8
    IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.
    IC87201
  • HY-109139
    Taminadenant 1337962-47-6 99.84%
    Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response.
    Taminadenant
  • HY-13027G
    DAPT (GMP) 208255-80-5
    DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor.
    DAPT (GMP)
  • HY-12498
    GV-58 1402821-41-3 99.22%
    GV-58 is a novel N- and P/Q-type calcium (Ca2+) channel agonist with EC50s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca2+ entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research.
    GV-58
  • HY-12844
    Ro 64-6198 280783-56-4 ≥99.0%
    Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC50 value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia.
    Ro 64-6198
Cat. No. Product Name / Synonyms Application Reactivity